Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial

Oliveira, Mafalda ✉; Rugo, Hope S.; Howell, Sacha J.; Dalenc, Florence; Cortes, Javier; Gomez, Henry L.; Hu, Xichun; Toi, Masakazu; Jhaveri, Komal; Krivorotko, Petr; Loibl, Sibylle; Murillo, Serafin Morales; Okera, Meena; Nowecki, Zbigniew; Park, Yeon Hee; Sohn, Joo Hyuk; Tokunaga, Eriko; Yousef, Samih; Zhukova, Lyudmila; Fulford, Marta; Andrews, Haylee; Wadsworth, Ian; D'Cruz, Celina; Turner, Nicholas C.; CAPItello-291 Study Grp [Kollaborációs szervezet]